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ALPHA-INTERFERON IN A CASE OF HYPEREOSINOPHILIC SYNDROME 
We have read with interest the report of Murphy et a1 (1990) 
on the use of alpha-interferon (a-IFN) in a case of hypereosi- 
nophilic syndrome (HES). Their patient with severe HES 
showed a dramatic clinical and haematological improvement 
with the introduction of recombinant a-IFN. However, 
follow-up was only 3 months. 
We also treated a patient with HES using a-IFN (Essex). 
This led to a good response. However, in a longer follow-up 
we observed that the response lasted only 6 months. 
In a 43-year-old man HES was diagnosed in October 198 7 
according to the diagnostic criteria of HES as outlined by 
Chusid et a1 (1975). His initial evaluation revealed a white 
blood count (WBC) of 11 3 x 10y/l with 90% eosinophils. 1% 
polymorphonuclear leucocytes, 8% lymphocytes and 1 % 
monocytes. The bone marrow examination showed hypercel- 
M a r  marrow with a marked predominance of eosinophilic 
precursors (77%). There was no excess of blast cells. The 
neutrophil alkaline phosphatase score and karyotype were 
normal. His spleen was enlarged and in the lungs bilateral 
transient infiltrations were found. Renal function was de- 
creased. An echocardiogram revealed a restrictive cardio- 
myopathy with pulmonal hypertension and tricuspid-regur- 
gitation. The patient had no HLA-identical sibling donor. He 
was initially treated with hydroxyurea and prednisone. 
without further clinical or haematological improvement. As 
his condition worsened, IFN was commenced in October 
1988. He received 5 x 10" units subcutaneously daily. In the 
first 4 months of IFN therapy the WBC decreased from 120 to 
10.6 x 109/1 with 90% eosinophils and his condition 
improved dramatically. The congestive heart failure was 
controlled by diuretics and afterload reduction. There was 
stable disease until March 1989. Then IFN was stopped 
because of progression of the HES. Hydroxyurea was started 
again, but the WBC rose to 126 x 10y/l. He developed 
progressive congestive heart failure due to thickening of the 
mural endocardium of the right ventricle and tricuspid valve 
destruction. Endomyocardial biopsy showed marked fibrosis 
in the subendocardium. Despite continued activity of the 
underlying disease, he had cardiac surgery in February 
1990. The mitral and tricuspid valves were replaced and 
thrombotic masses were removed from the right ventricle. 
His clinical condition improved dramatically after the sur- 
gery. Unexpectedly he died of cardiorespiratory failure in 
April 1990. 
HES is an extremely rare disease. Our experience shows 
that IFN has a place in the treatment of HES and we think it 
has to be given early in the treatment. However, the 
haematological response may only be short, as in our patient, 
although every response may postpone the tissue damage 
which makes this disease fatal. 
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APLASTIC PANCYTOPENIA INSTEAD OF THE MISNOMER APLASTIC ANAEMIA 
In his Blood, Textbook ofHernatology of 198 7 Jandl writes on p. 
1 13:  'Pancytopenia arising from inclusive failure of marrow 
parenchymal elements is customarily termed aplastic anemia 
or hypoplastic anemia. This confusing convention has 
generated alternative expressions such as chronic bone 
marrow failure, but in hematologic parlance aplastic anemia 
is the accepted and predominant designation for pancytope- 
nia arising from impaired activity of pluripotential stem cells.' 
I am sure that most haematologists agree with Jandl that it 
would have been less confusing if the condition characterized 
by pancytopenia due to lack of progenitors for each of the 
three cell lines in the bone marrow had been named aplastic 
today in most textbooks and haematological usage means 
lowered numbers of all three cell lines in the blood, regardless 
of cause or mechanism. 
Although haematologists would welcome a change from 
aplastic anaemia to the logical term aplastic pancytopenia. 
most of them doubt that it can be achieved. A decision by the 
British Journal of Haematology to replace the misnomer 
aplastic anaemia in its columns with aplastic pancytopenia, 
might give the necessary push to start the changing ava- 
lanche. Pancytopenia unqualified could then without risk of 
confusion be used to describe lowered numbers of all three 
cell lines in the blood, regardless of cause. 
pancytopenia rather than the misnomer aplastic anaemia. 
Additional confusion is caused by the International Classi- 
fication of Diseases which uses pancytopenia as a synonym 
for aplastic anaemia. This is unfortunate as pancytopenia 
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